US cell therapies firm Promethera secures investment from ITOCHU
ITOCHU is the first lead investor in Promethera’s new investment round, which is expected to be completed in the first quarter of this year. The US pharma firm is
China’s National Medical Products Administration (NMPA) has granted marketing authorisation for Bio-Thera Solutions’ BAT2506 to treat ankylosing spondylitis and rheumatoid arthritis.